The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumResearch - A recording of last night’s webinar is ready and available for on-demand viewing. This month focused almost exclusively on your requested topics/companies. Timestamps: 2:00 Macro … Continue Reading
PremiumLong Ideas - The first efficacy data for SAGE-217, the oral follow-on to Sage Therapeutics’ (SAGE) injectable neurosteroid SAGE-547, are out, and they’re encouraging. Recall that SAGE-547 is … Continue Reading
PremiumLong Ideas - Last July, Ultragenyx Pharmaceutical (RARE) released positive results from a phase 3 study of its enzyme replacement therapy rhGUS (recombinant human beta-glucuronidase) in the lysosomal … Continue Reading
Read nowResearch - Over last weekend, Pharmathene (PIP) affected a special one-time cash dividend of $2.91 per share of common stock. This is money received from its long-running … Continue Reading
PremiumResearch - Despite continued claims to the contrary, ArQule is a fairly weak MET inhibitor, and some publications question this proposed mechanism entirely
PremiumInsights - After a much-needed meeting between pharmaceutical representatives and Donald Trump this morning, biopharma stocks are rallying. To summarize, Trump’s comments after the meeting (a 10-minute … Continue Reading
Read nowResearch - Last night’s webcast is now available for replay. Topics of discussion included the Trump presidency, drug prices, and healthcare reform in 2017. We also introduced … Continue Reading
Premium
